Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(bupropion naltrexone)
260 results
  • Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. [Review]
    Ann Transl Med 2019; 7(16):393Montan PD, Sourlas A, … Kosmas CE
  • Obesity is a chronic, relapsing, multifactorial disease, which has become a serious threat to public health globally, as the worldwide prevalence of obesity increases exponentially over time. It has been well established that obesity is associated with multiple adverse cardiometabolic effects. Although lifestyle changes are the first line of therapy for obesity, these are often insufficient in atta…
  • Methamphetamine Use: A New Wave in the Opioid Crisis? [Journal Article]
    J Addict Nurs 2019 Jul/Sep; 30(3):219-223Fogger SA
  • The ongoing drug crisis in the United States continues to be headlined with numbers of deaths related to opioid overdose. Less known to the public and health care providers is the rise in methamphetamine use, often in conjunction with opioids or adulterated with fentanyl. An old practice with a new twist is the use of methamphetamine in conjunction with an opioid such as heroin.
  • [Current approaches to the treatment and correction of Internet addiction]. [Journal Article]
    Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119(6):152-159Egorov AY, Grechanyi SV
  • According to WHO consensus decision, gambling disorder, including the form of Internet addiction (IA), should be included in the section 'Impulsive disorders and behavioral addictions' of ICD-11. Population studies in the USA and Europe show the prevalence of IA from 1.5 to 8.2%, and in the countries of Southeast Asia it reaches 20-30% among young people. All this raises questions about the devel…
  • [Pharmacological treatment of obesity for Primary Care physicians]. [Review]
    Semergen 2019Rubio Herrera MA, Fernández-García JM, … Urieta Carpi JJ
  • Obesity is a disease of high prevalence in Primary Care clinics. It is associated with major comorbidities (dyslipidaemia, diabetes, hypertension) that increase morbidity and mortality, health expenditure, and reduces the quality of life of patients. Changes in lifestyle are still the pillars of the treatment of excess weight. Pharmacological treatment should be considered when there are difficul…
    Endocr Pract 2019; 25(10):1022-1028Shibuya K, Ali KF, … Burguera B
  • CONCLUSIONS: In real-world practice, AOMs are associated with clinically meaningful weight loss of 2 to 4% after 12 weeks. In this study, phentermine hydrochloride and phentermine topiramate produced the most weight loss. AOMs should be seriously considered as part of the armamentarium to treat patients with obesity. Abbreviations: AOM = anti-obesity medication; BMI = body mass index; EMR = electronic medical record; FDA = Food and Drug Administration; T2D = type 2 diabetes.
  • The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. [Review]
    Folia Med (Plovdiv) 2018; 60(4):512-520Chatzis P, Tziomalos K, … Dinas K
  • Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age. Obesity is frequently present in these patients and plays a key role in the pathogenesis of both the endocrine and metabolic abnormalities of the syndrome, particularly infertility, hyperandrogenism and insulin resistance (IR). Diet and exercise is the mainstay of management of obesity in patients w…
  • Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis. [Journal Article]
    Int J Clin Res Trials 2019; 4(1)Kane JA, Mehmood T, … McFarlane SI
  • CONCLUSIONS: Our study demonstrated the favorable and significant effect of pharmacological weight reduction strategies on weight loss, blood pressure reduction, glycemic control (A1C reduction), and CVD mortality.While weight loss without pharmacological means has been shown to reduce CVD risk, the mechanism by which weight loss medications impact CVD risk reduction could be a direct effect of these agents or merely an effect of weight reduction itself. Weight loss has been noted to modify risk factors via improving insulin sensitivity, reducing inflammation, decreasing blood pressure and modifying the lipid profile, In addition, the mechanism of action of the medications are not directly anti-inflammatory, and do not directly modify insulin sensitivity, blood pressure or the lipid profile. Thus, it is most likely that the benefit on cardiovascular disease from these therapies is via weight reduction and not direct medication effect.Given the limited efficacy of the lifestyle modification on sustained weight loss and the surgical risk and limited availability of bariatric surgical options. Our data suggests pharmacological weight loss therapy may be a valuable treatment option to reduce CVD risk in obese patients. Further research is needed to clarify the effects these therapies on overall mortality and evaluate the mechanisms by which these medications reduce CVD risk factors and mortality.
New Search Next